金价，涨了

Group 1: Federal Reserve and Market Reactions - The Federal Reserve's monetary policy outlook remains a key concern for the market, with recent hawkish statements from officials causing panic, but New York Fed President Williams indicated that the current labor market weakness poses a greater threat to the economy than inflation, suggesting further rate cuts may be possible [1] - Following Williams' dovish comments, market expectations for a 25 basis point rate cut in December rose to over 70%, alleviating investor concerns [1] - The S&P Global reported that U.S. business activity expanded at its fastest pace in four months in November, with service sector growth accelerating and overall economic outlook improving, leading to gains in the three major U.S. stock indices [1] Group 2: Company Developments - Eli Lilly became the first pharmaceutical company globally to surpass a market capitalization of $1 trillion, driven by expanded production and strong performance of its weight loss drugs [7] - Goldman Sachs projected that Eli Lilly's oral version of its weight loss drug is expected to launch in Q1 next year, earlier than anticipated, which could enhance its market share [7] - Eli Lilly's agreement with the U.S. government to significantly reduce prices for some weight loss drugs is expected to broaden its drug coverage and increase sales potential [7] Group 3: European Economic Indicators - In Europe, the S&P Global and Hamburg Commercial Bank reported a significant drop in new orders due to weak demand, with the Eurozone manufacturing PMI falling to 49.7 in November, indicating contraction [9] - Major economies like Germany and France showed weakened manufacturing growth momentum, with their PMIs falling further into contraction territory [9] - European stock indices showed mixed results, with the UK FTSE 100 and France's CAC40 slightly up, while Germany's DAX index declined [9]